Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(5):412-413; doi:10.1093/jnci/djh071
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Barr, E.
Right arrow Articles by Koutsky, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barr, E.
Right arrow Articles by Koutsky, L. A.
Related Collections
Right arrowCorrespondence about this Article
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

CORRESPONDENCE

Re: Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles

Eliav Barr, Laura A. Koutsky

Affiliations of authors: Biologics Clinical Research, Merck Research Laboratories, West Point, PA (EB); HPV Research Group, Department of Epidemiology, University of Washington, Seattle (LAK).

Correspondence to: Eliav Barr, MD, Biologics Clinical Research, Merck Research Laboratories, West Point, PA 19486-0004 (e-mail: eliav_barr@ merck.com)

The first 10% of the full text of this article appears below.

We read with interest the article by Nardelli-Haefliger et al. (1) in which the authors reported an approximate ninefold reduction in cervical anti-human papillomavirus 16 (HPV16) immunoglobulin (Ig; specific IgG and total IgG and IgA) levels at the time of ovulation in 11 women who received aluminum-free (i.e., adjuvant-free) HPV16 L1 virus-like particle (VLP) vaccine synthesized in a baculovirus system (1). The authors hypothesized that the efficacy of prophylactic HPV16 . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Correspondence about this Article

RESPONSE: Re: Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles
Douglas R. Lowy, Denise Nardelli-Haefliger, Allan Hildesheim, and John T. Schiller
J Natl Cancer Inst 2004 96: 413-414. [Extract] [Full Text] [PDF]